hypoglycemic agents

Summary

Summary: Agents which lower the blood glucose level.

Top Publications

  1. pmc Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16
    Gijs W D Landman
    Internal Medicine, Isala Clinics, Zwolle, The Netherlands
    Diabetes Care 33:322-6. 2010
  2. ncbi Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
    D M Nathan
    Diabetes Center, Massachusetts General Hospital, Boston, MA 02114, USA
    Diabetologia 52:17-30. 2009
  3. ncbi Effect of treatment of gestational diabetes mellitus on pregnancy outcomes
    Caroline A Crowther
    Department of Obstetrics and Gynaecology, University of Adelaide, Adelaide, Australia
    N Engl J Med 352:2477-86. 2005
  4. ncbi Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes
    Olivia J Phung
    University of Connecticut School of Pharmacy, Storrs, and Drug Information Center, Hartford Hospital, Hartford, Connecticut 06102 5037, USA
    JAMA 303:1410-8. 2010
  5. pmc Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
    William C Knowler
    Diabetes Prevention Program Coordinating Center, Biostatistics Center, George Washington University, 6110 Executive Blvd, Suite 750, Rockville, MD 20852, USA
    N Engl J Med 346:393-403. 2002
  6. pmc Role of AMP-activated protein kinase in mechanism of metformin action
    G Zhou
    Department of Molecular Endocrinology, Merck Research Laboratories, Rahway, New Jersey 07065, USA
    J Clin Invest 108:1167-74. 2001
  7. ncbi The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
    Daniel J Drucker
    Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
    Lancet 368:1696-705. 2006
  8. pmc Metformin and reduced risk of cancer in diabetic patients
    Josie M M Evans
    Division of Community Health Sciences, Section of Public Health, University of Dundee, Dundee DD2 4BF
    BMJ 330:1304-5. 2005
  9. doi Effects of intensive glucose lowering in type 2 diabetes
    Hertzel C Gerstein
    N Engl J Med 358:2545-59. 2008
  10. ncbi Effect of a multifactorial intervention on mortality in type 2 diabetes
    Peter Gaede
    Steno Diabetes Center, Copenhagen, Denmark
    N Engl J Med 358:580-91. 2008

Detail Information

Publications277 found, 100 shown here

  1. pmc Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16
    Gijs W D Landman
    Internal Medicine, Isala Clinics, Zwolle, The Netherlands
    Diabetes Care 33:322-6. 2010
    ..Several studies have suggested an association between specific diabetes treatment and cancer mortality. We studied the association between metformin use and cancer mortality in a prospectively followed cohort...
  2. ncbi Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
    D M Nathan
    Diabetes Center, Massachusetts General Hospital, Boston, MA 02114, USA
    Diabetologia 52:17-30. 2009
    ..In this revision, we focus on the new classes of medications that now have more clinical data and experience...
  3. ncbi Effect of treatment of gestational diabetes mellitus on pregnancy outcomes
    Caroline A Crowther
    Department of Obstetrics and Gynaecology, University of Adelaide, Adelaide, Australia
    N Engl J Med 352:2477-86. 2005
    ..We conducted a randomized clinical trial to determine whether treatment of women with gestational diabetes mellitus reduced the risk of perinatal complications...
  4. ncbi Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes
    Olivia J Phung
    University of Connecticut School of Pharmacy, Storrs, and Drug Information Center, Hartford Hospital, Hartford, Connecticut 06102 5037, USA
    JAMA 303:1410-8. 2010
    ..Metformin is the recommended initial drug therapy for patients with type 2 diabetes mellitus (DM). However, the optimal second-line drug when metformin monotherapy fails is unclear...
  5. pmc Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
    William C Knowler
    Diabetes Prevention Program Coordinating Center, Biostatistics Center, George Washington University, 6110 Executive Blvd, Suite 750, Rockville, MD 20852, USA
    N Engl J Med 346:393-403. 2002
    ..We hypothesized that modifying these factors with a lifestyle-intervention program or the administration of metformin would prevent or delay the development of diabetes...
  6. pmc Role of AMP-activated protein kinase in mechanism of metformin action
    G Zhou
    Department of Molecular Endocrinology, Merck Research Laboratories, Rahway, New Jersey 07065, USA
    J Clin Invest 108:1167-74. 2001
    ..Activation of AMPK provides a unified explanation for the pleiotropic beneficial effects of this drug; these results also suggest that alternative means of modulating AMPK should be useful for the treatment of metabolic disorders...
  7. ncbi The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
    Daniel J Drucker
    Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
    Lancet 368:1696-705. 2006
    ..However, long-term clinical studies are needed to determine the benefits of targeting the incretin axis for the treatment of type 2 diabetes...
  8. pmc Metformin and reduced risk of cancer in diabetic patients
    Josie M M Evans
    Division of Community Health Sciences, Section of Public Health, University of Dundee, Dundee DD2 4BF
    BMJ 330:1304-5. 2005
  9. doi Effects of intensive glucose lowering in type 2 diabetes
    Hertzel C Gerstein
    N Engl J Med 358:2545-59. 2008
    ....
  10. ncbi Effect of a multifactorial intervention on mortality in type 2 diabetes
    Peter Gaede
    Steno Diabetes Center, Copenhagen, Denmark
    N Engl J Med 358:580-91. 2008
    ..We evaluated whether this approach would have an effect on the rates of death from any cause and from cardiovascular causes...
  11. pmc Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state
    Marc Foretz
    Institut Cochin, Universite Paris Descartes, CNRS UMR 8104, Paris, France
    J Clin Invest 120:2355-69. 2010
    ..In conclusion, we demonstrate that metformin inhibits hepatic gluconeogenesis in an LKB1- and AMPK-independent manner via a decrease in hepatic energy state...
  12. doi Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
    Anushka Patel
    N Engl J Med 358:2560-72. 2008
    ..In patients with type 2 diabetes, the effects of intensive glucose control on vascular outcomes remain uncertain...
  13. pmc The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin
    Reuben J Shaw
    Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA
    Science 310:1642-6. 2005
    ..Finally, we show that metformin, one of the most widely prescribed type 2 diabetes therapeutics, requires LKB1 in the liver to lower blood glucose levels...
  14. ncbi 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
    Baptist Gallwitz
    Department of Medicine IV, Universitatsklinikum Tubingen, Tubingen, Germany
    Lancet 380:475-83. 2012
    ..We aimed to compare a dipeptidyl peptidase-4 inhibitor (linagliptin) against a commonly used sulphonylurea (glimepiride)...
  15. pmc Diabetes and cancer: a consensus report
    Edward Giovannucci
    Department of Nutrition, Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA
    Diabetes Care 33:1674-85. 2010
    ..In addition, key unanswered questions for future research are posed...
  16. pmc FGF-21 as a novel metabolic regulator
    Alexei Kharitonenkov
    Lilly Research Laboratories, Division of Eli Lilly and Co, Indianapolis, Indiana 46285, USA
    J Clin Invest 115:1627-35. 2005
    ..Thus, we conclude that FGF-21, which we have identified as a novel metabolic factor, exhibits the therapeutic characteristics necessary for an effective treatment of diabetes...
  17. ncbi 10-year follow-up of intensive glucose control in type 2 diabetes
    Rury R Holman
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism, Churchill Hospital, Headington, Oxford OX3 7LJ, United Kingdom
    N Engl J Med 359:1577-89. 2008
    ..We conducted post-trial monitoring to determine whether this improved glucose control persisted and whether such therapy had a long-term effect on macrovascular outcomes...
  18. pmc Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
    David M Nathan
    Diabetes Center, Massachusetts General Hospital, Boston, Massachusetts, USA
    Diabetes Care 32:193-203. 2009
    ..In this revision, we focus on the new classes of medications that now have more clinical data and experience...
  19. ncbi The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
    C J Currie
    School of Medicine, Cardiff University, The Pharma Research Centre, Cardiff Medicentre, Cardiff, CF14 4UJ, UK
    Diabetologia 52:1766-77. 2009
    ..We examined the risk of development of solid tumours in relation to treatment with oral agents, human insulin and insulin analogues...
  20. ncbi Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes
    T Heise
    Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
    Diabetes Obes Metab 14:859-64. 2012
    ..Insulin degludec (IDeg) is a new-generation basal insulin with an ultra-long duration of action. We compared the pharmacodynamic (PD) variability of IDeg and insulin glargine (IGlar) under steady-state conditions...
  21. pmc Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer
    Sao Jiralerspong
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, 77030 4009, USA
    J Clin Oncol 27:3297-302. 2009
    ..Our purpose was to determine whether metformin use was associated with a change in pathologic complete response (pCR) rates in diabetic patients with breast cancer receiving neoadjuvant chemotherapy...
  22. pmc Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas, USA
    Diabetes Care 35:1232-8. 2012
    ..To evaluate the effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in type 2 diabetes mellitus inadequately controlled with metformin monotherapy...
  23. ncbi Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
    Michael Elashoff
    Larry L Hillblom Islet Research Center at David Geffen School of Medicine and Department of Biomathematics, University of California, Los Angeles, California 90095 7073, USA
    Gastroenterology 141:150-6. 2011
    ..There are also concerns that dipeptidyl peptidase-4 inhibitors could cause cancer, given their effects on immune function...
  24. pmc Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study
    A Neumann
    Caisse Nationale de l Assurance Maladie, 50 Avenue du Pr André Lemierre, 75986 Paris Cedex 20, France
    Diabetologia 55:1953-62. 2012
    ..Previous studies have suggested an increased risk of bladder cancer with pioglitazone exposure. We aimed to investigate the association between pioglitazone exposure and bladder cancer in France...
  25. ncbi Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I
    M Y El-Mir
    Laboratoire de Bioénergétique Fondamentale et Appliquée, Universite Joseph Fourier, F 38041 Grenoble Cedex 09, France
    J Biol Chem 275:223-8. 2000
    ....
  26. ncbi Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group
    R C Turner
    Radcliffe Infirmary, Oxford, England
    JAMA 281:2005-12. 1999
    ..8 mmol/L (140 mg/dL) or glycosylated hemoglobin A1c (HbA1c) below 7% is unknown...
  27. ncbi Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth
    Monica Buzzai
    Abramson Family Cancer Research Institute, Department of Cancer Biology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Cancer Res 67:6745-52. 2007
    ..Thus, metformin is selectively toxic to p53-deficient cells and provides a potential mechanism for the reduced incidence of tumors observed in patients being treated with metformin...
  28. pmc Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
    Tina Vilsbøll
    Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, DK 2900 Hellerup, Denmark
    BMJ 344:d7771. 2012
    ..To determine whether treatment with agonists of glucagon-like peptide-1 receptor (GLP-1R) result in weight loss in overweight or obese patients with or without type 2 diabetes mellitus...
  29. pmc Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study
    M Peyrot
    Department of Sociology, Loyola University of Maryland, Baltimore, MD 21210 2699, USA
    Diabet Med 29:682-9. 2012
    ..To examine patient and physician beliefs regarding insulin therapy and the degree to which patients adhere to their insulin regimens...
  30. pmc Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
    D Russell-Jones
    Department of Diabetes and Endocrinology, Royal Guildford Hospital, UK
    Diabetologia 52:2046-55. 2009
    ..The aim of the study was to compare the efficacy and safety of liraglutide in type 2 diabetes mellitus vs placebo and insulin glargine (A21Gly,B31Arg,B32Arg human insulin), all in combination with metformin and glimepiride...
  31. pmc Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study
    James D Lewis
    Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Diabetes Care 34:916-22. 2011
    ..This is an interim report of an ongoing cohort study examining the association between pioglitazone therapy and the risk of bladder cancer in patients with diabetes...
  32. pmc Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
    K Stenlof
    Clinical Trial Center, Sahlgrenska University Hospital, Gothenburg, Sweden
    Diabetes Obes Metab 15:372-82. 2013
    ..Canagliflozin is a sodium glucose co-transporter 2 inhibitor in development for type 2 diabetes mellitus (T2DM). The efficacy and safety of canagliflozin were evaluated in subjects with T2DM inadequately controlled with diet and exercise...
  33. pmc Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long)
    Bernard Zinman
    Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
    Diabetes Care 35:2464-71. 2012
    ..To compare ultra-long-acting insulin degludec with glargine for efficacy and safety in insulin-naive patients with type 2 diabetes inadequately controlled with oral antidiabetic drugs (OADs)...
  34. ncbi Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes
    T Heise
    Profil Institute for Metabolic Research, Neuss, Germany
    Diabetes Obes Metab 14:944-50. 2012
    ..This double-blind, two-period, incomplete block cross-over trial investigated the pharmacodynamic and pharmacokinetic properties of IDeg at steady state (SS) in people with type 2 diabetes...
  35. pmc Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis
    Davide Soranna
    Dipartimento di Epidemiologia, Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, Milan, Italy
    Oncologist 17:813-22. 2012
    ..To quantify the association between metformin and sulfonylurea and the risk of cancer, we performed a meta-analysis of available studies on the issue...
  36. ncbi The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1)
    A Ramachandran
    Diabetes Research Centre, M V Hospital for Diabetes, WHO Collaborating Centre for Research, Education and Training in Diabetes, Royapuram, Chennai, India
    Diabetologia 49:289-97. 2006
    ..In a prospective community-based study, we tested whether the progression to diabetes could be influenced by interventions in native Asian Indians with IGT who were younger, leaner and more insulin resistant than the above populations...
  37. ncbi Glucose control and vascular complications in veterans with type 2 diabetes
    William Duckworth
    Phoenix Veterans Affairs Health Care Center, Phoenix, AZ 85012, USA
    N Engl J Med 360:129-39. 2009
    ..The effects of intensive glucose control on cardiovascular events in patients with long-standing type 2 diabetes mellitus remain uncertain...
  38. pmc Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials
    Rémy Boussageon
    Department of General Medicine, Universite Claude Bernard Lyon 1, Lyon, France
    BMJ 343:d4169. 2011
    ..To determine all cause mortality and deaths from cardiovascular events related to intensive glucose lowering treatment in people with type 2 diabetes...
  39. ncbi DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes
    Thomas Blevins
    Texas Diabetes and Endocrinology, 6500 North Mopac Expressway, Building 3, Suite 200, Austin, Texas 78731, USA
    J Clin Endocrinol Metab 96:1301-10. 2011
    ..We wanted to understand the effects of once-weekly vs. twice-daily glucagon-like peptide-1 receptor agonism for treatment of patients with type 2 diabetes...
  40. ncbi Severe hypoglycemia and risks of vascular events and death
    Sophia Zoungas
    George Institute for International Health, University of Sydney, Sydney, Australia
    N Engl J Med 363:1410-8. 2010
    ..We analyzed data from a large study of intensive glucose lowering to explore the relationship between severe hypoglycemia and adverse clinical outcomes...
  41. pmc Antidiabetic therapies affect risk of pancreatic cancer
    Donghui Li
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Gastroenterology 137:482-8. 2009
    ..We investigated the effect of antidiabetic therapies on the risk of pancreatic cancer...
  42. ncbi AMP-activated protein kinase in metabolic control and insulin signaling
    Mhairi C Towler
    Division of Molecular Physiology, College of Life Sciences, University of Dundee, Dundee, Scotland, UK
    Circ Res 100:328-41. 2007
    ..It is a key player in the development of new treatments for obesity, type 2 diabetes, and the metabolic syndrome...
  43. pmc Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)
    Vivian A Fonseca
    Department of Medicine, Tulane University Health Sciences Center, New Orleans, Louisiana, USA
    Diabetes Care 35:1225-31. 2012
    ..To assess efficacy and safety of lixisenatide monotherapy in type 2 diabetes...
  44. pmc Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin
    Ib Jonassen
    Diabetes Research Unit, Novo Nordisk, Novo Nordisk Park, 2760, Måløv, Denmark
    Pharm Res 29:2104-14. 2012
    ..A series of insulins, acylated at B29 with fatty acids via glutamic acid spacers, were examined to deduce the structural requirements...
  45. ncbi Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin
    D Devineni
    Janssen Research and Development, LLC, Raritan, NJ 08869, USA
    Diabetes Obes Metab 14:539-45. 2012
    ..Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that is being investigated for the treatment of type 2 diabetes mellitus (T2DM)...
  46. ncbi Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
    Simon Heller
    University of Sheffield, Sheffield, UK eld ac uk
    Lancet 379:1489-97. 2012
    ..We therefore compared the efficacy and safety of insulin degludec and insulin glargine, both administered once daily with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes...
  47. ncbi The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level
    I Ben Sahra
    INSERM U568, Nice, France
    Oncogene 27:3576-86. 2008
    ....
  48. ncbi Thiazolidinediones
    Hannele Yki-Jarvinen
    Division of Diabetes, Department of Medicine, University of Helsinki, Finland
    N Engl J Med 351:1106-18. 2004
  49. ncbi AMPK: an emerging drug target for diabetes and the metabolic syndrome
    Bei B Zhang
    Department of Metabolic Disorders, Merck Research Laboratories, Rahway, NJ 07065, USA
    Cell Metab 9:407-16. 2009
    ..Activation of AMPK by pharmacological agents presents a unique challenge, given the complexity of the biology, but holds a considerable potential to reverse the metabolic abnormalities associated with type 2 diabetes...
  50. ncbi Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects
    S Sha
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Raritan, NJ 08869, USA
    Diabetes Obes Metab 13:669-72. 2011
    ..Canagliflozin was generally well tolerated; most adverse events were mild and no hypoglycaemia was reported. These results support further study of canagliflozin...
  51. ncbi Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis
    Andrea Decensi
    Division of Medical Oncology Unit, EO Ospedali Galliera, Mura delle Cappuccine 14, 16128 Genoa, Italy
    Cancer Prev Res (Phila) 3:1451-61. 2010
    ..Given the retrospective nature of most studies and the possibility that the control treatments increase risk, phase II trials are needed before large cancer prevention trials are launched...
  52. pmc Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis
    Hiroshi Noto
    Department of Diabetes and Metabolic Medicine, Center Hospital, National Center for Global Health and Medicine, Tokyo, Japan
    PLoS ONE 7:e33411. 2012
    ..Our objective was to enhance the precision of estimates of the effect of metformin on the risk of any-site and site-specific cancers in patients with diabetes...
  53. ncbi Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin
    Samantha L Bowker
    Institute of Health Economics, Edmonton, Alberta, Canada
    Diabetes Care 29:254-8. 2006
    ..We explored the association between antidiabetic therapies and cancer-related mortality in patients with type 2 diabetes, postulating that agents that increase insulin levels might promote cancer...
  54. pmc New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes
    Gillian Libby
    Division of Clinical and Population Sciences and Education, University of Dundee, Dundee, UK
    Diabetes Care 32:1620-5. 2009
    ..Activation of AMPK can suppress tumor formation and inhibit cell growth in addition to lowering blood glucose levels. We tested the hypothesis that metformin reduces the risk of cancer in people with type 2 diabetes...
  55. pmc Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis
    Clare L Gillies
    Centre for Biostatistics and Genetic Epidemiology, Department of Health Sciences, University of Leicester, Leicester LE1 7RH
    BMJ 334:299. 2007
    ..To quantify the effectiveness of pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance...
  56. pmc Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study
    Janet B McGill
    Division of Endocrinology, Metabolism and Lipid Research, Washington University in St Louis, St Louis, MO, USA
    Diabetes Care 36:237-44. 2013
    ..This placebo-controlled study assessed long-term efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes and severe renal impairment (RI)...
  57. pmc Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)
    Y Seino
    Kansai Electric Power Hospital, Osaka, Japan
    Diabetes Obes Metab 14:910-7. 2012
    ..To assess the efficacy and safety of once-daily lixisenatide versus placebo in Asian patients with type 2 diabetes insufficiently controlled on basal insulin ± sulfonylurea...
  58. ncbi International trial of the Edmonton protocol for islet transplantation
    A M James Shapiro
    Clinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada
    N Engl J Med 355:1318-30. 2006
    ..We conducted an international, multicenter trial to explore the feasibility and reproducibility of islet transplantation with the use of a single common protocol (the Edmonton protocol)...
  59. ncbi Diabetes and cancer: a consensus report
    Edward Giovannucci
    Departments of Nutrition and Epidemiology, Harvard School of Public Health, 655 Huntington Avenue, Boston, MA 02115, USA
    CA Cancer J Clin 60:207-21. 2010
    ..In addition, key unanswered questions for future research are posed...
  60. ncbi Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial
    John B Buse
    University of North Carolina School of Medicine, Chapel Hill, 27599, USA
    Ann Intern Med 154:103-12. 2011
    ..Insulin replacement in diabetes often requires prandial intervention to reach hemoglobin A₁(c) (HbA₁(c)) targets...
  61. pmc Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study
    L G Hemkens
    Institute for Quality and Efficiency in Health Care IQWiG, Dillenburger Strasse 27, D 51105, Cologne, Germany
    Diabetologia 52:1732-44. 2009
    ..The aim of this cohort study was to investigate the risk of malignant neoplasms and mortality in patients with diabetes treated either with human insulin or with one of three insulin analogues...
  62. ncbi Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
    N Engl J Med 356:2457-71. 2007
    ..Rosiglitazone is widely used to treat patients with type 2 diabetes mellitus, but its effect on cardiovascular morbidity and mortality has not been determined...
  63. ncbi Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64)
    Amanda I Adler
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, and South Cleveland Hospital, Cleveland, United Kingdom
    Kidney Int 63:225-32. 2003
    ..This study sought to describe the development and progression through the stages of microalbuminuria, macroalbuminuria, persistently elevated plasma creatinine or renal replacement therapy (RRT), and death...
  64. ncbi Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study
    Craig J Currie
    Department of Medicine, School of Medicine, Cardiff University, Cardiff, UK
    Lancet 375:481-9. 2010
    ..Results of intervention studies in patients with type 2 diabetes have led to concerns about the safety of aiming for normal blood glucose concentrations. We assessed survival as a function of HbA(1c) in people with type 2 diabetes...
  65. pmc Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
    David M Nathan
    N Engl J Med 353:2643-53. 2005
    ..We studied whether the use of intensive therapy as compared with conventional therapy during the Diabetes Control and Complications Trial (DCCT) affected the long-term incidence of cardiovascular disease...
  66. pmc Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation
    Simon A Hawley
    Division of Molecular Physiology, College of Life Sciences, University of Dundee, Dundee DD1 5EH, Scotland, UK
    Cell Metab 11:554-65. 2010
    ..Our approaches distinguish at least six different mechanisms for AMPK activation and confirm that the widely used antidiabetic drug metformin activates AMPK by inhibiting mitochondrial respiration...
  67. doi Summary and recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus
    Boyd E Metzger
    Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
    Diabetes Care 30:S251-60. 2007
  68. pmc Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets
    J Hans DeVries
    Department of Internal Medicine, Academic Medical Centre, Amsterdam, The Netherlands
    Diabetes Care 35:1446-54. 2012
    ..We evaluated the addition of liraglutide to metformin in type 2 diabetes followed by intensification with basal insulin (detemir) if glycated hemoglobin (A1C) ≥7%...
  69. pmc Metformin and the risk of cancer: time-related biases in observational studies
    Samy Suissa
    Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Canada
    Diabetes Care 35:2665-73. 2012
    ..Immortal time bias, time-window bias, and time-lag bias all tend to greatly exaggerate the benefits observed with a drug...
  70. pmc Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial
    Faramarz Ismail-Beigi
    Department of Medicine, Division of Clinical and Molecular Endocrinology, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106 4951, USA
    Lancet 376:419-30. 2010
    ..We investigated whether reduction of blood glucose concentration decreases the rate of microvascular complications in people with type 2 diabetes...
  71. ncbi Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes
    James Mu
    Department of Metabolic Disorders, Merck Research Laboratories, P O Box 2000, Rahway, NJ 07065, USA
    Diabetes 55:1695-704. 2006
    ..These findings suggest that DPP-4 inhibitors may offer long-lasting efficacy in the treatment of type 2 diabetes by modifying the courses of the disease...
  72. ncbi The impact of non-severe hypoglycemic events on work productivity and diabetes management
    Meryl Brod
    The BROD GROUP, Mill Valley, CA 94941, USA
    Value Health 14:665-71. 2011
    ..The objective of this multi-country study was to identify how NSHEs in a working population affect productivity, costs, and self-management behaviors...
  73. ncbi Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
    Richard M Bergenstal
    International Diabetes Center at Park Nicollet, Minneapolis, MN 55416, USA
    Lancet 376:431-9. 2010
    ....
  74. ncbi Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden
    J M Jonasson
    Division of Clinical Cancer Epidemiology, Department of Oncology, Onkologiskt centrum, Sahlgrenska Academy, 41345, Gothenburg, Sweden
    Diabetologia 52:1745-54. 2009
    ..In the light of a report suggesting that insulin glargine may increase cancer occurrence, the EASD asked us to perform this study...
  75. ncbi Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
    Michaela Diamant
    Diabetes Centre, VU University Medical Centre, Amsterdam, Netherlands
    Lancet 375:2234-43. 2010
    ..We aimed to test the hypothesis that improvement in haemoglobin A(1c) (HbA(1c)) achieved with once weekly exenatide was superior to that achieved with insulin glargine titrated to glucose targets...
  76. ncbi Investigating metformin for cancer prevention and treatment: the end of the beginning
    Michael N Pollak
    Department of Oncology, McGill University, Montreal, Quebec, Canada
    Cancer Discov 2:778-90. 2012
    ....
  77. ncbi Long-term effects of insulin glargine on the risk of breast cancer
    S Suissa
    Center for Clinical Epidemiology, Lady Davis Research Institute, Jewish General Hospital, 3755 Cote Ste Catherine, Montreal, QC, Canada H3T 1E2
    Diabetologia 54:2254-62. 2011
    ..There have been growing concerns regarding the long-term effects of insulin glargine (A21Gly,B31Arg,B32Arg human insulin) on the risk of breast cancer...
  78. ncbi Medicinal plants of India with anti-diabetic potential
    J K Grover
    Department of Pharmacology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110049, India
    J Ethnopharmacol 81:81-100. 2002
    ..charantia, Eugenia jambolana, Mucuna pruriens, T. cordifolia, T. foenum graecum, O. sanctum, P. marsupium, Murraya koeingii and Brassica juncea. All plants have shown varying degree of hypoglycemic and anti-hyperglycemic activity...
  79. pmc Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes
    Kaixin Zhou
    Biomedical Research Institute, University of Dundee, Dundee, UK
    Nat Genet 43:117-20. 2011
    ..We conclude that ATM, a gene known to be involved in DNA repair and cell cycle control, plays a role in the effect of metformin upstream of AMP-activated protein kinase, and variation in this gene alters glycemic response to metformin...
  80. pmc Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study
    David Russell-Jones
    Department of Diabetes and Endocrinology, Royal Surrey County Hospital, University of Surrey, Guildford, UK
    Diabetes Care 35:252-8. 2012
    ..To test the safety and efficacy of exenatide once weekly (EQW) compared with metformin (MET), pioglitazone (PIO), and sitagliptin (SITA) over 26 weeks, in suboptimally treated (diet and exercise) drug-naive patients with type 2 diabetes...
  81. ncbi Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure
    S L Bowker
    Department of Public Health Sciences, School of Public Health, University of Alberta, 2 040 Health Research Innovation Facility, Edmonton, AB, Canada T6G 2E1
    Diabetologia 53:1631-7. 2010
    ..We explored the relationship between glucose-lowering agents and cancer mortality rates in type 2 diabetes patients, hypothesising a decreased risk of cancer mortality with metformin use and a dose-risk gradient for insulin therapy...
  82. ncbi Metformin: an update
    Dmitri Kirpichnikov
    State University of New York Health Science Center at Brooklyn, 450 Clarkson Avenue, Box 1205, Brooklyn, New York 11203, USA
    Ann Intern Med 137:25-33. 2002
    ....
  83. pmc Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4
    Masayuki Arakawa
    Department of Medicine, Metabolism and Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan
    Diabetes 59:1030-7. 2010
    ..The aim of this study was to investigate the effects of GLP-1 on accumulation of monocytes/macrophages on the vascular wall, one of the earliest steps in atherosclerogenesis...
  84. pmc Long-term metformin use is associated with decreased risk of breast cancer
    Michael Bodmer
    Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland
    Diabetes Care 33:1304-8. 2010
    To evaluate whether use of oral hypoglycemic agents is associated with an altered breast cancer risk in women.
  85. pmc Validation of anti-aging drugs by treating age-related diseases
    Mikhail V Blagosklonny
    Cancer Center, Ordway Research Institute, Albany, NY 12208, USA
    Aging (Albany NY) 1:281-8. 2009
    ..If the group is large, then the anti-aging effect could be validated in a couple of years. Startlingly, retrospective analysis of clinical and preclinical data reveals four potential anti-aging modalities...
  86. pmc Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group
    H M Colhoun
    Biomedical Research Institute, University of Dundee, Mackenzie Building, Kirsty Semple Way, Dundee, DD2 4BF, Scotland, UK
    Diabetologia 52:1755-65. 2009
    ..The aim of the present study was to examine whether patients with diabetes in Scotland using insulin glargine have a greater cancer risk than patients using other types of insulin...
  87. ncbi Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
    Peter Gaede
    Steno Diabetes Center, Copenhagen, Denmark
    N Engl J Med 348:383-93. 2003
    ....
  88. ncbi The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways
    Lee G D Fryer
    Cellular Stress Group, Medical Research Council Clinical Sciences Centre, Hammersmith Hospital, DuCane Road, London W12 0NN, United Kingdom
    J Biol Chem 277:25226-32. 2002
    ..Our results demonstrate that AMPK can be activated by at least two distinct signaling mechanisms and suggest that it may play a wider role in the cellular stress response than was previously understood...
  89. pmc The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study
    Michael E Miller
    Division of Public Health Sciences, Wake Forest University School of Medicine, Winston Salem, NC 27157 1063, USA
    BMJ 340:b5444. 2010
    ....
  90. pmc Correlates of insulin injection omission
    Mark Peyrot
    Department of Sociology, Loyola University Maryland, Baltimore, Maryland, USA
    Diabetes Care 33:240-5. 2010
    ..The purpose of this study was to assess factors associated with patient frequency of intentionally skipping insulin injections...
  91. pmc Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine
    Kare I Birkeland
    Oslo University Hospital and Faculty of Medicine, Oslo, Norway
    Diabetes Care 34:661-5. 2011
    ..We assessed the efficacy and safety of IDeg formulations administered once daily in combination with mealtime insulin aspart in people with type 1 diabetes...
  92. pmc Metformin activates AMP kinase through inhibition of AMP deaminase
    Jiangyong Ouyang
    Department of Pathology, New York University School of Medicine, New York, New York 10010, USA
    J Biol Chem 286:1-11. 2011
    ..Both metformin and the AMPD inhibitor suppressed ammonia accumulation by the cells. Knockdown of AMPD obviated metformin stimulation of glucose transport. We conclude that AMPD inhibition is the mechanism of metformin action...
  93. ncbi Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study
    Ralph A DeFronzo
    University of Texas Health Science Center, Department of Medicine, Diabetes Division MSC 7886, 7703 Floyd Curl Drive, San Antonio, TX 78229 3900, USA
    Curr Med Res Opin 24:2943-52. 2008
    ..This study evaluated the effects of exenatide, a GLP-1 receptor agonist, and sitagliptin, a DPP-4 inhibitor, on 2-h postprandial glucose (PPG), insulin and glucagon secretion, gastric emptying, and caloric intake in T2D patients...
  94. ncbi Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality
    Steven E Nissen
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Arch Intern Med 170:1191-1201. 2010
    ..Controversy regarding the effects of rosiglitazone therapy on myocardial infarction (MI) and cardiovascular (CV) mortality persists 3 years after a meta-analysis initially raised concerns about the use of this drug...
  95. ncbi Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
    Philip D Home
    Newcastle Diabetes Centre and Newcastle University, Newcastle upon Tyne, UK
    Lancet 373:2125-35. 2009
    ..We assessed cardiovascular outcomes after addition of rosiglitazone to either metformin or sulfonylurea compared with the combination of the two over 5-7 years of follow-up. We also assessed comparative safety...
  96. ncbi Systematic review: glucose control and cardiovascular disease in type 2 diabetes
    Tanika N Kelly
    Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, 1440 Canal Street, Suite 2000, New Orleans, LA 70112, USA
    Ann Intern Med 151:394-403. 2009
    ..Results from clinical trials examining the effect of intensive glucose control on cardiovascular disease have been conflicting...
  97. ncbi Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
    Richard E Pratley
    Diabetes and Metabolism Translational Medicine Unit, University of Vermont College of Medicine, Burlington, VT, USA
    Lancet 375:1447-56. 2010
    ....
  98. ncbi Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006
    Bernard M Y Cheung
    Department of Clinical Pharmacology, School of Clinical and Experimental Medicine, University of Birmingham, United Kingdom
    Am J Med 122:443-53. 2009
    ..Changes in the prevalence, treatment, and management of diabetes in the United States from 1999 to 2006 were studied using data from the National Health and Nutrition Examination Survey...
  99. pmc Gender differences in metformin effect on aging, life span and spontaneous tumorigenesis in 129/Sv mice
    Vladimir N Anisimov
    N N Petrov Research Institute of Oncology, Pesochny 2, St Petersburg 197758, Russia
    Aging (Albany NY) 2:945-58. 2010
    ..5 times the incidence of malignant neoplasms in female mice while somewhat stimulated formation of benign vascular tumors in the latter...
  100. pmc Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database
    Jennie H Best
    Amylin Pharmaceuticals, San Diego, California, USA
    Diabetes Care 34:90-5. 2011
    ..To test the hypothesis that exenatide twice daily reduces the relative incidence of cardiovascular disease (CVD) events among patients with type 2 diabetes compared with other glucose-lowering agent(s)...
  101. pmc The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study
    Denise E Bonds
    National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    BMJ 340:b4909. 2010
    ..To determine whether there is a link between hypoglycaemia and mortality among participants in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial...

Research Grants62

  1. Ginkgo Biloba Extract & The Insulin Resistance Syndrome
    George Kudolo; Fiscal Year: 2004
    ..mechanism may involve the alteration of drug pharmacokinetics resulting in decreased efficacy of the hypoglycemic agents and increased whole body insulin resistance...
  2. Effective treatment of sleep apnea in prediabetes to reduce cardiometabolic risk
    Esra Tasali; Fiscal Year: 2010
    ..The results of this research may provide a better understanding of ways to prevent and/or treat diabetes and its cardiovascular complications for millions of Americans. ..
  3. A rational approach to liver toxicity monitoring in methotrexate users
    Gabriela Schmajuk; Fiscal Year: 2013
    ..This mentored career development award will provide the skills, mentorship, and experience necessary to propel her to independence. ..
  4. Synergistic Roles of Adiponectin & PPARgamma in Beta-Cell Survival/Proliferation
    William L Holland; Fiscal Year: 2010
    ..The PANIC ATTAC mouse allows the unique opportunity to evaluate beta cell regeneration following the cell specific and titratable induction of apoptosis. ..
  5. Modulation of PKC Response and Insulin Secretion by the Beta Subunit of Calcium C
    GANESAN LENIN KAMATCHI; Fiscal Year: 2013
    ..To be specific, this Aim will identify the Ser/Thr PKC phosphorylation sites of Cav [unreadable]1 subunits that are targeted by the Cav[unreadable] and PKC isozymes and study the mechanism of interaction between these three proteins. ..
  6. Biobehavioral Bases &Management of Type 2 Diabetes and Depression
    Neil Schneiderman; Fiscal Year: 2011
    ..abstract_text> ..
  7. A Cardiovascular Risk Reduction Learning Community in DARTNet
    Karl Hammermeister; Fiscal Year: 2010
    ..ability to conduct observational comparative effectiveness research in a completed pilot project on oral hypoglycemic agents. Working collaboratively with DARTNet care providers, we will analyze three groups of factors associated ..
  8. Discovery and Development of Novel Glucose Dependent Partial Glucokinase Activato
    Duncan McRee; Fiscal Year: 2010
    ..After identification of several lead K-system GKA series, we intend to implement structure guided medicinal chemistry campaign to develop a partial GKAs with pharmaceutical like properties. ..
  9. Impact of Medicaid Policy on cardiovascular drug use and clinical outcomes
    Michael A Fischer; Fiscal Year: 2010
    ....
  10. Glucose lowering effect of metformin and sitagliptin in adolescents with Type 1
    Luisa M Rodriguez; Fiscal Year: 2013
    ..is to improve glycemic control in adolescents with Type 1 diabetes mellitus (T1DM) through the use of oral hypoglycemic agents as adjuncts to insulin therapy...
  11. The Role of PPARgamma in Lung Cancer Progression and Metastasis
    Howard Li; Fiscal Year: 2013
    ..Such an environment maximizes the potential for the applicant to establish a scientific niche from which an academic career can be constructed. ..
  12. Targeting diet-induced promotion of Kras-initiated pancreatic adenocarcinoma
    GUIDO ERWIN MICHAEL EIBL; Fiscal Year: 2013
    ..abstract_text> ..
  13. Low-cost proinsulin-transferrin fusion protein in rice for treatment of diabetes
    Deshui Zhang; Fiscal Year: 2013
    ..Therefore, there is an urgent need to develop novel, inexpensive hypoglycemic agents to treat and arrest the fast spreading of this debilitating disease...
  14. Silymarin for the Treatment of Nonalcoholic Steatohepatitis
    Victor J Navarro; Fiscal Year: 2010
    ..These results will allow practitioners and patients to decide whether to use Silymarin in this specific disease process. ..
  15. FRUCTOFURANOSE MODULATORS--STRUCTURAL/ENZYMATIC STUDIES
    EZZAT YOUNATHAN; Fiscal Year: 1992
    ..This discovery revealed a new group of hypoglycemic agents hitherto unstudied...
  16. PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR EXPRESSION
    NICOLAS GUZMAN; Fiscal Year: 2001
    ..abstract_text> ..
  17. Novel Puerarin Analogs with Anti-Diabetic Activity
    NICHOLAS CAIRNS; Fiscal Year: 2007
    ..this proposal are to synthesize novel puerarin analogs and to evaluate the potential of these compounds as hypoglycemic agents. To accomplish this goal, we will synthesize novel puerarin analogs and screen them for their ability to ..
  18. Novel Alkylglycosides with Anti-Diabetic Activity
    NICHOLAS CAIRNS; Fiscal Year: 2005
    ..Testing of the Alkylmaltosides as Substrates for the Glycogen Biosynthetic Enzymes 4. Determine the Effects of the Most Active O- and/or S-Alkylmaltosides on Blood Glucose and Glucose tolerance in the ob/ob Mouse Model. ..
  19. NOVEL HYPOGLYCEMIC AGENTS FROM DIOSCOREA SPP
    MICHAEL TEMPESTA; Fiscal Year: 1990
    The objective of the proposed project is to identify and evaluate novel hypoglycemic agents obtained from a plant used in folk medicine...
  20. HEREDITARY DIABETES
    DOUGLAS COLEMAN; Fiscal Year: 1990
    ..Once the most effect dosages and the toxicity are established, these new oral hypoglycemic agents may become significant in the treatment of human diabetes...
  21. Discovery and development of Antidiabetic Drugs
    GERARD HOUSEY; Fiscal Year: 2003
    ..Since diabetes is a major chronic disease of epidemic proportions, pharmaceutical products developed by at HPRL will have large market opportunities world-wide. ..
  22. NEUROCHEMICAL AND BEHAVIORAL EFFECTS OF HYPERGLYCEMIA
    MARISE PARENT; Fiscal Year: 2004
    ..abstract_text> ..
  23. Therapeutic Targeting of PPAR in Diabetic Nephropathy
    Youfei Guan; Fiscal Year: 2007
    ..abstract_text> ..
  24. Modeling Prioritization of Health Care for Complex Patients Using Archimedes.
    Dewey Scheid; Fiscal Year: 2009
    ..interventions and different classes of medications, including aspirin, antihypertensive medications, hypoglycemic agents, and lipid-lowering drugs...
  25. THE EFFECT OF TOLBUTAMIDE ON THE ISCHEMIC MYOCARDIUM
    Stephen Schaffer; Fiscal Year: 1980
    Oral hypoglycemic agents such as tolbutamide have been widely used to treat diabetes-induced hyperglycemia since their clinical introduction 20 years ago...
  26. CELLULAR MARKERS OF GENETIC HETEROGENEITY IN DIABETES
    THOMAS GELEHRTER; Fiscal Year: 1980
    ..The effect of incubation of the cells with glucocorticoids and oral hypoglycemic agents on their insulin responsiveness will also be studied...
  27. WEIGHT LOSS/EXERCISE IN AGED BLACKS WITH CHRONIC DISEASE
    TANYA AGURS; Fiscal Year: 1991
    ..Inclusion criteria include have a diagnosis of NIDDM treated with diet alone or with diet and oral hypoglycemic agents; >120% desirable body weight, but <160% desirable body weight, and not taking cholesterol-lowering ..
  28. Induced islet neogenesis therapy in vivo
    Lawrence Chan; Fiscal Year: 2007
    unreadable] DESCRIPTION (provided by applicant): Despite the development of oral hypoglycemic agents that boost insulin secretion or reduce insulin resistance, and of different forms of insulin with widely varying durations of action, ..
  29. Identification of an endogenous PPAR gamma ligand
    JONATHAN HAMM; Fiscal Year: 2003
    ..This work will be the foundation for a research program investigating the role of natural PPARgamma ligands in health and disease. ..
  30. OUTCOMES OF INCREASING SELF-MONITORING IN AN HMO
    Stephen Soumerai; Fiscal Year: 2000
    ..analysis, the project would stratify the results by patients receiving insulin and those receiving oral hypoglycemic agents, and also examine low-income patients and those with poor glycemic control...
  31. Mechanisms and use of antidiabetic agents in brain aging and Alzheimer's disease
    Olivier Thibault; Fiscal Year: 2008
    ..Furthermore, these studies will contribute to future drug discovery efforts to generate new TZD-derived or similar drugs for the treatment of AD. [unreadable] [unreadable] [unreadable]..
  32. Incremental Clinical/Cost Effect of RN/Peer
    Athena Philis Tsimikas; Fiscal Year: 2007
    ..unreadable] From a public health perspective this research may demonstrate culturally appropriate approaches that lead to positive behavior change and are clinically effective in the Latino diabetic population. [unreadable] [unreadable]..
  33. Silibinin in Prostate Cancer Chemoprevention & Treatment
    Michael Pollak; Fiscal Year: 2004
    ..The work is justified by the favorable toxicity profile of silibinin, together with prior positive laboratory studies reported by our group and other investigators. ..
  34. Inflammation in obesity: Modulation by Weight Loss
    Paresh Dandona; Fiscal Year: 2009
    ..abstract_text> ..
  35. Insulin Resistance and Hepatic Steatosis in Hepatitis C
    Charles F Burant; Fiscal Year: 2010
    ..abstract_text> ..
  36. GLUCOCORTICOIDS, HYPOGLYCEMIA & BRAIN GLUCOSE TRANSPORT
    Anthony McCall; Fiscal Year: 2001
    ..These studies should provide insight into hypoglycemia's impact upon the brain. They may potentially lead to safer was to achieve good diabetes control. ..
  37. Using Systems Biology to Understand Islet Adaptation and Failure Diabetes
    Charles F Burant; Fiscal Year: 2010
    ..The studies will also provide the first insights into the ways in which human islets react to specific nutrient challenges. ..
  38. Course and risk factors for depression in late life
    Hillary R Bogner; Fiscal Year: 2010
    ....
  39. Bone loss with aging occurs due to increased PPAR-g activity in marrow stem cells
    BEATA ANNA LECKA CZERNIK; Fiscal Year: 2010
    ..Completion of the above aims should enable us to determine the role of PPARg in this process and will allow designing therapeutic interventions that will selectively block PPARg anti-osteoblastic activity. ..
  40. Adherence to Depression Treatment Among Older Patients
    Hillary Bogner; Fiscal Year: 2007
    ..This project will set the stage for the development and implementation of interventions to improve depression treatment adherence among persons with co-existing CVD. ..
  41. Markers of normoglycemic remission in obese diabetics
    Guillermo Umpierrez; Fiscal Year: 2006
    ..Identifying such markers will facilitate and guide future therapeutic interventions and may identify patients at risk to develop chronic complications of diabetes ..
  42. Generation of Collecting Duct Knockout of PPARgamma
    Tianxin Yang; Fiscal Year: 2006
    ..New information provided by this proposal is expected to provide insights into the roles of PPARgamma in regulation of fluid balance and in mediation of the side effects of TDZ. ..
  43. Role of Glycogen Synthase Kinase 3 In Type 2-Diabetes
    Robert Henry; Fiscal Year: 2004
    ..abstract_text> ..
  44. Leptin and insulin action in the brain; role in obesity
    Kevin Niswender; Fiscal Year: 2007
    ..These aims also provide the background and training necessary for the development of an independent research program and will be conducted in the context of rich training environment ..
  45. Interaction of COX-2 AND nNOS in renin secretion (R01)
    Tianxin Yang; Fiscal Year: 2008
    ..abstract_text> ..
  46. PPAR gamma-2 expression in marrow stroma during aging
    Beata Lecka Czernik; Fiscal Year: 2005
    ..Such intervention may slow down or even prevent age-related bone loss. ..
  47. Renal medullary COX-2 in blood pressure control
    Tianxin Yang; Fiscal Year: 2008
    ..The information resulted from these studies will provide new insight into the molecular mechanism responsible for long-term control of arterial blood pressure. ..
  48. Characteristics and Costs of Impaired Fasting Glucose
    Gregory Nichols; Fiscal Year: 2005
    ..Finally, we will calculate and compare the costs of medical care for patients in each FPG stage, and estimate multivariate models to identify factors that contribute to medical costs in each stage. ..
  49. Brain insulin and leptin resistance in obesity
    Kevin Niswender; Fiscal Year: 2008
    ..Aim 4: To determine if genetic enhancement of the hypothalamic PI3K pathway enhances insulin and leptin sensitivity and attenuates DIO. ..
  50. Interaction of COX-2 and nNOS in renin secretion
    Tianxin Yang; Fiscal Year: 2006
    ....
  51. PAI-1 and The Vascular Toxicity of Aldosterone
    Nancy Brown; Fiscal Year: 2005
    ..This multi-disciplinary approach will generate new information regarding the role of aldosterone in vascular toxicity and, thus, improve our ability to prevent and treat cardiovascular disease. ..
  52. WHY DO METABOLIC RISK FACTORS CLUSTER WITH HYPERTENSION?
    Theodore Kurtz; Fiscal Year: 2003
    ....
  53. Data Evaluation for Early Disease Outbreak Detection
    Kenneth Kleinman; Fiscal Year: 2007
    ..abstract_text> ..
  54. BRAIN ENERGY METABOLISM AND HYPOGLYCEMIA
    Patrick Boyle; Fiscal Year: 2003
    ..Better metabolic control, the key to the prevention of long-term complications of diabetes, will thus become more achievable. ..
  55. IDENTIFICATION OF SUSCEPTIBILITY GENES FOR NIDDM
    ANDRZEJ KROLEWSKI; Fiscal Year: 2004
    ..abstract_text> ..
  56. RAAS, Inflammation & Post-Operative Atrial Fibrillation
    Nancy Brown; Fiscal Year: 2009
    ..abstract_text> ..
  57. Sex steroid, HPA regulation, and fat patterning
    Jonathan Purnell; Fiscal Year: 2003
    ..abstract_text> ..
  58. Mapping genes for proteinuria in type II diabetes
    Andrzej S Krolewski; Fiscal Year: 2010
    ..Furthermore while the proposed study aims to limit genetic and phenotypic heterogeneity to increase effectiveness, the generalizability of the findings will be verified by examining multi-center collections such as GoKinD and FIND. ..